Tiragolumab is an immune checkpoint inhibitor that binds to T-cell immunoglobulin and the structural domain of ITIM (TIGIT), targets TIGIT and has an intact Fc region. Tiragolumab is indicated for use in studies related to solid tumors.
Purity:
99.0%
CAS Number:
[1918185-84-8]
Target:
TIGIT
* VAT and and shipping costs not included. Errors and price changes excepted